Trials / Unknown
UnknownNCT02812134
Impact of Oral Phosphorus Supplements on the 6-month Change in FGF23 Levels in Anorexic Adolescents Suffering From Undernutrition.
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- Centre Hospitalier Universitaire, Amiens · Academic / Other
- Sex
- All
- Age
- 11 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
Fibroblast growth factor 23 (FGF23) is a recently discovered phosphaturic hormone produced by osteocytes. It is involved in phosphate-calcium metabolism (via its phosphaturic action and inhibition of 1,25-OH vitamin D). There are no published studies on the role of FGF23 in undernourished anorexic adolescents taking oral phosphorus supplements.
Conditions
Timeline
- Start date
- 2015-06-01
- Primary completion
- 2018-08-01
- Completion
- 2018-08-01
- First posted
- 2016-06-24
- Last updated
- 2018-08-21
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02812134. Inclusion in this directory is not an endorsement.